ArticleBasic research in cardiology2025
Pericardial adipose tissue promotes transition to heart failure with reduced ejection fraction upon pressure-overload in mice.
Article in Basic research in cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Orally Available Ghrelin Receptor-Agonist AC01 Improves Systolic Function in HFrEF Mice and Nonhuman Primates.JACC. Basic to translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In patients, severity of pressure-induced heart failure (HF) due to aortic stenosis and metabolic disorder correlates with thickness and mass of epicardial adipose tissue (EAT). We examined the role of the less studied pericardial adipose tissue (PAT) during manifestation and progression of pressure-induced HF in mice. Progressive remodeling was assessed in C57BL/6 J males, aged 9 weeks, following sham surgery or transverse aortic constriction (TAC) for 1 week (early pressure-overload), 8 (chronic pressure-overload), or 12 weeks (HF with reduced ejection fraction, HFrEF) with or without concomitant PAT excision. PAT removal did not affect early (1-week TAC) or chronic (8 weeks) pressure-overload-induced concentric remodeling. However, initial PAT excision prevented lung congestion, progressive LV dilation and systolic dysfunction and thereby protected against transition to HFrEF. This protection was associated with alleviation of early TAC-induced pro-inflammatory monocyte and macrophage expansion, attenuation of persistent pro-hypertrophic, pro-inflammatory and pro-fibrotic LV gene expression and the reduction of microscar and perivascular fibrosis in the long term. The latter was reflected by reduced peri-coronary accumulation of pro-fibrotic CD206
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.